Current Status Of Immunotherapy For Cervical Cancer

Abstract

Cervical cancer is one of the common gynecological malignancies that threaten women's health. Its etiology is complex, among which persistent human papillomavirus (HPV) infection is the main pathogenic factor. Due to the lack of obvious early symptoms, many patients are already in the middle and late stages when diagnosed. Although conventional chemotherapy can alleviate the disease, some patients will still experience recurrence or metastasis, indicating that the existing treatment methods are still limited. In recent years, immunotherapy technology has been continuously improved, especially the application of immune checkpoint inhibitors (ICIs) has provided a new direction for the treatment of cervical cancer. This article systematically reviews the common treatment methods and emerging immunosuppressive treatment strategies for cervical cancer, including chemotherapy, radiotherapy, anti-angiogenic therapy and bispecific immunoconjugates, and discusses their basic principles, mechanisms of action and drug side effects. Although some immunotherapy regimens have shown certain efficacy in clinical practice, existing studies are still insufficient in terms of drug diversity and mechanism interpretation. In the future, more new immunosuppressive drugs and treatment methods need to be further developed to improve the prognosis and survival rate of patients with cervical cancer.